EIK1005-002: Eine klinische Forschungsstudie zur Bewertung von EIK1005, einem Werner-Helicase-Inhibitor, als Monotherapie und in Kombination mit Pembrolizumab bei Teilnehmern mit fortgeschrittenen soliden Tumoren einschließlich Tumoren mit hoher Mikrosatelliteninstabilität (MSI-H)
Eine multizentrische, mehrteilige Phase-1/2-Studie von EIK1005 als Monotherapie und in Kombination mit Pembrolizumab bei Teilnehmern mit fortgeschrittenen soliden Tumoren, einschließlich checkpointinhibitor-naiver Teilnehmer mit Mikrosatelliteninstabilität-Hoch (MSI-H) oder Mismatch-Repair-Defizienz (dMMR) Tumoren
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.
The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:
- Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
- Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
- Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Ana C Mamede, PharmD
- Telefonnummer: 347-806-4584
- E-Mail: mamedea@eikontx.com
Studieren Sie die Kontaktsicherung
- Name: Krishna Kaza
- E-Mail: kazak@eikontx.com
Studienorte
-
-
New South Wales
-
Saint Leonards, New South Wales, Australien
- Noch keine Rekrutierung
- GenesisCare North Shore (Oncology)
-
Waratah, New South Wales, Australien
- Rekrutierung
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Ballarat, Victoria, Australien
- Rekrutierung
- Grampians Health
-
Camperdown, Victoria, Australien
- Rekrutierung
- Chris O'Brien Lifehouse (Sydney Cancer Centre)
-
Frankston, Victoria, Australien
- Rekrutierung
- Peninsula and Southeast Oncology (PASO) Medical
-
Frankston, Victoria, Australien, 3199
- Rekrutierung
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
-
-
-
-
-
Brussels, Belgien, 1020
- Rekrutierung
- Centre Hospitalier Universitaire Brugmann - Victor Horta
-
-
-
-
-
Berlin, Deutschland, 13125
- Rekrutierung
- Helios Klinikum Berlin-Buch
-
Hamburg, Deutschland, 22297
- Rekrutierung
- Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
-
-
Bavaria
-
Deggendorf, Bavaria, Deutschland, 94469
- Rekrutierung
- DONAUISAR Klinikum
-
-
-
-
-
Kuopio, Finnland, 70210
- Rekrutierung
- Kuopio University Hospital
-
-
-
-
Rhone
-
Pierre-Bénite, Rhone, Frankreich, 69310
- Rekrutierung
- Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
-
-
-
-
-
Rome, Italien, 00128
- Rekrutierung
- Campus Bio-Medico di Rome University
-
-
-
-
-
Wellington, Neuseeland
- Rekrutierung
- Health New Zealand
-
-
Manawatu
-
Roslyn, Manawatu, Neuseeland, 4414
- Rekrutierung
- Palmerstone North Hospital
-
-
-
-
-
Oslo, Norwegen, 0379
- Rekrutierung
- Oslo University
-
-
-
-
-
Krakow, Polen, 31-864
- Rekrutierung
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
Lodz, Polen, 90-338
- Rekrutierung
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Polen, 70-419
- Rekrutierung
- One Day Med
-
-
-
-
-
Lisbon, Portugal, 1649-028
- Rekrutierung
- Hospital de Santa Maria
-
Loures, Portugal, 2674-514
- Rekrutierung
- Unidade Local de Saúde (ULS) Loures Odivelas
-
Porto, Portugal, 4200
- Rekrutierung
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
-
-
Lisbon District
-
Lisbon, Lisbon District, Portugal, 1500-650
- Rekrutierung
- Hospital da Luz Lisboa
-
-
-
-
-
Singapore, Singapur, 119074
- Rekrutierung
- National University Hospital (NUH)
-
-
Central Region
-
Singapore, Central Region, Singapur, 168583
- Rekrutierung
- National Cancer Centre Singapore (NCCS)
-
-
-
-
-
Barcelona, Spanien, 08023
- Rekrutierung
- START - Barcelona
-
Logroño, Spanien, 26006
- Rekrutierung
- START Rioja - Hospital de San Pedro
-
Madrid, Spanien, 28233
- Rekrutierung
- NEXT Madrid HUQSM
-
Zaragoza, Spanien, 50009
- Rekrutierung
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma, Balearic Islands, Spanien, 07120
- Rekrutierung
- Hospital Universitari Son Espases
-
-
Barcelona
-
Barcelona, Barcelona, Spanien, 8036
- Rekrutierung
- Hospital Clinic Barcelona
-
-
-
-
-
Seoul, Südkorea, 02841
- Rekrutierung
- Korea University Anam Hospital
-
Suwon, Südkorea, 16499
- Rekrutierung
- Ajou University School of Medicine & Graduate School of Medicine
-
-
Busan
-
Busan, Busan, Südkorea, 48108
- Rekrutierung
- Inje University-Haeundae Paik Hospital
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90027
- Rekrutierung
- California Research Institute (CRI)
-
-
Florida
-
Doral, Florida, Vereinigte Staaten, 33172
- Rekrutierung
- Omnicure Clinical Research
-
Hialeah, Florida, Vereinigte Staaten, 33013
- Rekrutierung
- Bioresearch Partner
-
Plantation, Florida, Vereinigte Staaten, 33322
- Rekrutierung
- Florida Clinical Trials Group
-
Tamarac, Florida, Vereinigte Staaten, 33321
- Rekrutierung
- Florida Clinical Trials Group - Tamarac
-
-
New Jersey
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Rekrutierung
- Morristown Medical Center
-
-
New York
-
Lake Success, New York, Vereinigte Staaten, 11042
- Rekrutierung
- START New York-Long Island
-
New York, New York, Vereinigte Staaten, 10022
- Rekrutierung
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Texas
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- START Dallas Fort Worth
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- University of Texas MD Anderson Cancer Center
-
-
-
-
-
Linz, Österreich, 4020
- Rekrutierung
- Ordensklinikum Linz Elisabethinen
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- is ≥ 18 years of age at the time of signing the informed consent.
- has a life expectancy of at least 3 months.
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- has an adequate organ and marrow function.
Key Exclusion Criteria:
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
- has received prior treatment with Werner (WRN) inhibitor.
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- has active tuberculosis.
- has any active infections requiring systemic therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Part 1A (Dose escalation, Monotherapy)
EIK1005 will be given as monotherapy in participants without alternative treatment options. |
EIK1005 is a selective inhibitor of the Werner helicase. |
|
Experimental: Part 1B (Dose escalation, Combination with pembrolizumab)
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors. |
EIK1005 is a selective inhibitor of the Werner helicase. Pembrolizumab is a PD-1 inhibitor. |
|
Experimental: Part 2 (Dose optimization, Monotherapy)
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A. |
EIK1005 is a selective inhibitor of the Werner helicase. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Dose-Limiting Toxicity (DLT) - Part 1
Zeitfenster: 21 Days
|
A DLT is a protocol-defined adverse event occurring during the DLT observation period. |
21 Days
|
|
Adverse Events (AEs) - Part 1 and Part 2
Zeitfenster: From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Number of participants reporting adverse events or serious adverse events. |
From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response (OR) - Part 1 and Part 2
Zeitfenster: Through study completion, an average of 2 years.
|
OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Duration of Response (DOR) - Part 1 and Part 2
Zeitfenster: Through study completion, an average of 2 years.
|
DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Disease Control (DC) - Part 1 and Part 2
Zeitfenster: Through study completion, an average of 2 years.
|
DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Progression-free survival (PFS) - Part 2
Zeitfenster: Through study completion, an average of 2 years.
|
PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first. |
Through study completion, an average of 2 years.
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Zeitfenster: Up to 1 year
|
AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Zeitfenster: Up to 1 year
|
AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Zeitfenster: Up to 1 year
|
Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Zeitfenster: Up to 1 year
|
tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Zeitfenster: Up to 1 year
|
Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienleiter: Nilou Mobashery, MD, Eikon Therapeutics, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Pathologische Prozesse
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Neoplastische Prozesse
- Genitale Neubildungen, weiblich
- Uterusneoplasmen
- Pathologische Zustände, Anzeichen und Symptome
- Neoplasma Metastasierung
- Endometriale Neubildungen
- Turcot -Syndrom
- Pembrolizumab
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- EIK1005-002
- 2026-525248-13-00 (Ctis)
- KEYNOTE-G56 (Andere Kennung: Merck Sharp & Dohme LLC)
- MK-3475-G56 (Andere Kennung: Merck Sharp & Dohme LLC)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .